CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 23/04/2025 BST			5-day change	1st Jan Change
109.00 ^USD	+1.97%		+2.25%	-40.95%

04-22	Charles River Laboratories International, Inc. Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development	CI
04-21	Jefferies Adjusts Price Target on Charles River Laboratories International to $100 From $169, Maintains Hold Rating	MT

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development	04-22	BU
Charles River Laboratories International, Inc. Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development	04-22	CI
Jefferies Adjusts Price Target on Charles River Laboratories International to $100 From $169, Maintains Hold Rating	04-21	MT
Baird Adjusts Price Target on Charles River Laboratories International to $118 From $101, Keeps Neutral Rating	04-17	MT
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call	04-15	BU
Equity Markets Close Higher After Latest Tariff Updates	04-14	MT
Equity Markets Rise as Investors Respond to Tariff News	04-14	MT
TD Cowen Adjusts Charles River Laboratories International's PT to $105 From $179, Keeps Hold Rating	04-14	MT
BofA Securities Cuts Charles River Laboratories International Price Target to $150 From $185	04-14	MT
Baird Adjusts PT on Charles River Laboratories International to $101 From $155, Keeps Neutral Rating	04-11	MT
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $140 From $210	04-11	MT
Earnings Upbeat as Trade Winds Shift	04-11
FDA no longer wants animal testing in laboratories	04-11
Analyst recommendations: Chevron, Carmax, KKR, Etsy, Nike…	04-11
Barclays Adjusts Price Target on Charles River Laboratories International to $145 From $160	04-10	MT
Evercore ISI Adjusts PT on Charles River Laboratories International to $135 From $175, Maintains In Line Rating	04-09	MT
Goldman Sachs Adjusts Charles River Laboratories International PT to $150 From $170, Maintains Neutral Rating	04-08	MT
Charles River Laboratories International, Inc Solicits Proxies from Shareholders	04-02	CI
People for the Ethical Treatment of Animals Submits Shareholder Proposals with Charles River Laboratories International, Inc	04-02	CI
Flagship Pioneering, Pfizer, Charles River and Valo Health Collaborate to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease	04-01	CI
Baird Adjusts Charles River Laboratories International Price Target to $155 From $173, Maintains Neutral Rating	03-31	MT
Charles River, Valo Health Identify First Lupus Treatment Candidate Using Logica AI Platform	03-25	MT
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform	03-25	BU
Charles River and Valo Health Identify A Potential Therapeutic for Lupus Using Logica	03-25	CI
Charles River Laboratories International, Inc.(NYSE:CRL) dropped from FTSE All-World Index	03-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Filters